Anne Herold Li

Anne Herold Li is a shareholder at Brownstein Hyatt Farber Schreck, where she serves as managing partner of the firm’s New York office and co-chairs its Life Sciences practice. A first-chair trial lawyer and member of a Chambers-ranked patent team, she focuses on intellectual property and litigation in the life-sciences industry. She trained and worked as an epidemiologist before becoming a lawyer, and holds her law degree from Fordham University School of Law.

She returned to Open Door Salon in July 2026 with Arcutis Biotherapeutics security leader Raja Mikkili, continuing a conversation the two began on a panel at BIO, to discuss what nation states actually target in biotech, why small and mid-size companies are the more valuable prize, and the data-ownership language buried in collaboration agreements that most CEOs have never read.

Her practice spans patent litigation, intellectual-property strategy, and the structuring of complex life-sciences transactions, work that places her at the center of the trade, tariff, and national-security questions now reshaping the industry. At the time of her appearance she was working on the Supreme Court cases over the administration’s tariffs, on behalf of a range of clients.

Herold Li appeared on Open Door Salon alongside Colin Zick, a partner at Foley Hoag, for a wide-ranging conversation on the legal and regulatory forces reshaping life sciences. She walked through what a tariff reversal would mean for the more than 300,000 companies that had paid them, the revival of the Bayh-Dole Act as a lever to force domestic manufacturing of federally funded inventions, and how dealmakers can structure China-linked biotech transactions around the returning Biosecure Act.

Her throughline was practical: the legal landscape is shifting on many fronts at once, but each shift creates a structuring or positioning question that a well-advised company can get ahead of rather than be caught by.